

Equitable Scientific Collaborations, Partnerships, and Coordination Within the US: *Industry Perspective*

- **COVID-19 Success, Strategies, Lessons learned**
 - Thinking differently
 - Leveraging previous research
 - Beneficial partnerships
 - Regulatory collaboration
- **COVID-19 Unprecedented Critical Points**
 - Lightspeed Paradigm
 - Parallel testing: Four candidates tested simultaneously
 - At Risk Investment: Investing without scientific validation
- **Health Equity Best Practices, Lessons learned**
 - Pfizer committed to equitable & affordable vaccine access
 - In 45,000 Phase III participants, 42% represented diverse backgrounds
 - Scientific nimbleness to adapt to changing landscape
 - More than 4.2 billion Pfizer-BioNTech COVID-19 vaccines shipped
 - Collaborative global partners

